Cargando…
200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation
BACKGROUND: Dalbavancin (DAL) received Food and Drug Administration (FDA) approval for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive organisms including Methicillin-resistant Staphylococcus aureus (MRSA). Due to its unique activity and dosing sc...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809837/ http://dx.doi.org/10.1093/ofid/ofz360.275 |
_version_ | 1783462094765555712 |
---|---|
author | Alosaimy, Sara Pearson, Jeffrey Veve, Michael Dionne, Brandon Aleissa, Muneerah Jorgensen, Sarah C J Rybak, Michael J |
author_facet | Alosaimy, Sara Pearson, Jeffrey Veve, Michael Dionne, Brandon Aleissa, Muneerah Jorgensen, Sarah C J Rybak, Michael J |
author_sort | Alosaimy, Sara |
collection | PubMed |
description | BACKGROUND: Dalbavancin (DAL) received Food and Drug Administration (FDA) approval for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive organisms including Methicillin-resistant Staphylococcus aureus (MRSA). Due to its unique activity and dosing schedule, use in non-FDA approved indications has been increasing. We evaluated the clinical and safety outcomes of patients treated with DAL for various infections. METHODS: A multicenter, retrospective observational study was conducted from April 2017 to February 2019. We included adult patients who received 1 dose of DAL for any indication. The primary outcome was clinical success defined as 30-day survival from DAL initiation, resolution of signs and symptoms of infection, and absence of therapy escalation/change. Reasons for DAL therapy selection were also investigated. RESULTS: A total of 30 patients were included. The median age was 49 (35–58) years, 50% were female and 93.3% were Caucasian. Median APACHE II score was 9 (5–12). Persons who inject drugs (PWID) comprised 50%. Common DAL indications were bacteremia (53.3%), bone and joint infections (33.3%) and ABSSSI (26.7%). Pathogens were MRSA (43.3%), coagulase-negative Staphylococci (23.3%) and methicillin-susceptible S. aureus (MSSA) (13.3%). Previous antibiotics were administered in 93.3% of patients for a median of 9 (7–15) days and (13.3%) received combination antibiotic therapy with DAL. In a subgroup of patients with confirmed microbiological eradication (73.3%), DAL was initiated at a median of 8 days (4–14) after clearance. Clinical success was achieved in 80% of patients and 10% were de-escalated to oral therapy. Rash/pruritus and hypotension occurred in two and one patient, respectively. DAL was selected because of ease of administration (60%), inability to be discharged with a line (43.3%), poor candidacy for outpatient therapy (36.7%), and/or inadequate adherence (30%). CONCLUSION: DAL appears to be well tolerated and results in high clinical success. Larger studies with longer follow would be valuable to more precisely define the role of DAL in complicated Gram-positive infections, particularly in comparison to other long-acting lipoglycopeptides. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6809837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68098372019-10-28 200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation Alosaimy, Sara Pearson, Jeffrey Veve, Michael Dionne, Brandon Aleissa, Muneerah Jorgensen, Sarah C J Rybak, Michael J Open Forum Infect Dis Abstracts BACKGROUND: Dalbavancin (DAL) received Food and Drug Administration (FDA) approval for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive organisms including Methicillin-resistant Staphylococcus aureus (MRSA). Due to its unique activity and dosing schedule, use in non-FDA approved indications has been increasing. We evaluated the clinical and safety outcomes of patients treated with DAL for various infections. METHODS: A multicenter, retrospective observational study was conducted from April 2017 to February 2019. We included adult patients who received 1 dose of DAL for any indication. The primary outcome was clinical success defined as 30-day survival from DAL initiation, resolution of signs and symptoms of infection, and absence of therapy escalation/change. Reasons for DAL therapy selection were also investigated. RESULTS: A total of 30 patients were included. The median age was 49 (35–58) years, 50% were female and 93.3% were Caucasian. Median APACHE II score was 9 (5–12). Persons who inject drugs (PWID) comprised 50%. Common DAL indications were bacteremia (53.3%), bone and joint infections (33.3%) and ABSSSI (26.7%). Pathogens were MRSA (43.3%), coagulase-negative Staphylococci (23.3%) and methicillin-susceptible S. aureus (MSSA) (13.3%). Previous antibiotics were administered in 93.3% of patients for a median of 9 (7–15) days and (13.3%) received combination antibiotic therapy with DAL. In a subgroup of patients with confirmed microbiological eradication (73.3%), DAL was initiated at a median of 8 days (4–14) after clearance. Clinical success was achieved in 80% of patients and 10% were de-escalated to oral therapy. Rash/pruritus and hypotension occurred in two and one patient, respectively. DAL was selected because of ease of administration (60%), inability to be discharged with a line (43.3%), poor candidacy for outpatient therapy (36.7%), and/or inadequate adherence (30%). CONCLUSION: DAL appears to be well tolerated and results in high clinical success. Larger studies with longer follow would be valuable to more precisely define the role of DAL in complicated Gram-positive infections, particularly in comparison to other long-acting lipoglycopeptides. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809837/ http://dx.doi.org/10.1093/ofid/ofz360.275 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Alosaimy, Sara Pearson, Jeffrey Veve, Michael Dionne, Brandon Aleissa, Muneerah Jorgensen, Sarah C J Rybak, Michael J 200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation |
title | 200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation |
title_full | 200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation |
title_fullStr | 200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation |
title_full_unstemmed | 200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation |
title_short | 200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation |
title_sort | 200. real-world experience with dalbavancin for complicated gram-positive infections: a multicenter evaluation |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809837/ http://dx.doi.org/10.1093/ofid/ofz360.275 |
work_keys_str_mv | AT alosaimysara 200realworldexperiencewithdalbavancinforcomplicatedgrampositiveinfectionsamulticenterevaluation AT pearsonjeffrey 200realworldexperiencewithdalbavancinforcomplicatedgrampositiveinfectionsamulticenterevaluation AT vevemichael 200realworldexperiencewithdalbavancinforcomplicatedgrampositiveinfectionsamulticenterevaluation AT dionnebrandon 200realworldexperiencewithdalbavancinforcomplicatedgrampositiveinfectionsamulticenterevaluation AT aleissamuneerah 200realworldexperiencewithdalbavancinforcomplicatedgrampositiveinfectionsamulticenterevaluation AT jorgensensarahcj 200realworldexperiencewithdalbavancinforcomplicatedgrampositiveinfectionsamulticenterevaluation AT rybakmichaelj 200realworldexperiencewithdalbavancinforcomplicatedgrampositiveinfectionsamulticenterevaluation |